MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Investigation of Modifiers of β-Glucocerebrosidase in Cell Models of Parkinson’s Disease

    A. Wernick, J. Evans, G. Virdi, M. Choi, D. Athauda, Z. Zanjani Shadman, H. Plun-Favreau, S. Wray, S. Gandhi (London, United Kingdom)

    Objective: We firstly aim to identify modifiers of β-glucocerebrosidase (GCase) activity and expression in Parkinson’s disease (PD) relevant cell models. We secondly aim to ascertain…
  • 2022 International Congress

    Nutritional Status of Patients with Parkinson’s Disease: Report from Indonesian Tertiary Referral Hospital

    SS. Musthafa, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: This study aimed to describe and determine the prevalence of nutritional status in outpatient Parkinson’s Disease (PD) patients. Background: Parkinson’s disease is the most…
  • 2022 International Congress

    Plasma p-tau181 is increased in Lewy body dementia and relates to cognitive performance

    N. Hannaway, A. Heslegrave, R. Bhome, I. Dobreva, H. Zetterberg, R. Weil (LONDON, United Kingdom)

    Objective: To compare plasma p-tau181 concentration in Parkinson’s disease (PD), Lewy body dementia (LBD) and healthy controls and to examine the relationship between ptau-181 concentration…
  • 2022 International Congress

    Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

    M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

    Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…
  • 2022 International Congress

    Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation

    A. Al-Sabbagh, S. Testino, M. Koga, T. Chase, K. Smith (Alpharetta, USA)

    Objective: To evaluate the pharmacokinetics (PK) of 25/100 mg carbidopa (CD)/levodopa (LD) compared to half that amount given twice as often using a new, deeply…
  • 2022 International Congress

    Alteration of peripheral blood cell profiles in Parkinson’s disease: a retrospective case-control study

    G. Tian, R. Zhou, X. Guo, R. Li (Xi'an, China)

    Objective: The aim of this study is to investigate the relationship between peripheral blood cell profiles and Parkinson's disease (PD). Background: Abnormal immune response and systemic inflammation have…
  • 2022 International Congress

    Examining adaptive control in patients with Parkinson’s disease

    J. Kricheldorff, J. Ficke, K. Witt (Oldenburg, Germany)

    Objective: To investigate whether proactive or reactive adaptive control are impaired in Parkinson’s disease (PD). Background: Adaptive control in patients with PD remains understudied, with…
  • 2022 International Congress

    Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.

    SW. Pedersen, L. Johannsen (Frederiksberg, Denmark)

    Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…
  • 2022 International Congress

    Long-term Safety of Medical Cannabis in Parkinson’s disease: a retrospective case-control study

    T. Goldberg, Y. Redlich, T. Fay-Karmon, S. Hassin-Baer, S. Anis (Tel Aviv, Israel)

    Objective: This study aims to evaluate the effects of long-term treatment with medical cannabis (MC) on the course of Parkinson’s disease (PD), with a focus…
  • 2022 International Congress

    GRIN2D is a cause of autosomal dominant form of Parkinson’s disease

    A. Kishore, M. Sturm, J. Shin, S. Grover, F. Raimondi, C. Blauwendraat, S. Robert, G. Sarma, N. Casadei, P. Lichtner, A. Kumar-Sreelatha, J. Winkelmann, R. Krüger, A. Singleton, T. Gasser, P. Seth, J. Roeper, O. Riess, M. Sharma (Kochi, India)

    Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…
  • « Previous Page
  • 1
  • …
  • 197
  • 198
  • 199
  • 200
  • 201
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley